Biocracked
Longevity Metabolism Peptides Research Supplements Trending: supplements longevity clinical trial healthy aging peptides
A bright, minimalist editorial still life on a pale warm-white stone surface, shot from a slightly elevated three-quarter angle in soft natural window light. At center, a small amber glass supplement bottle with a matte cream label, unbranded, sits beside a few loose white capsules. A pair of weathered hands in a light oatmeal linen sleeve, belonging to an older adult, rests gently near the bottle, with a ceramic mug of tea just out of focus. To the right, a clean glass vial and a delicate glass beaker filled with clear liquid catch the light, hinting at laboratory research without any futuristic touch. A small paper notebook with a handwritten simple line graph rising in a gentle curve lies open nearby, along with a sharpened pencil. Scattered at the edges are soft sprigs of dried eucalyptus and a few pale sage-green leaves, adding an organic note. A faint, abstract molecular diagram printed in muted teal ink on a card leans against the bottle, subtle and graphic. The palette is calm and modern: warm ivory, sage green, soft teal, muted amber, and touches of dusty peach. Long, gentle shadows fall across the surface, and the shallow depth of field blurs the background into creamy neutral tones. The composition leaves generous negative space on the left third for headline text. The overall feel is a trendy health and science journal: clean, airy, trustworthy, and quietly sophisticated, with fine film-like grain and true-to-life color. Ultra-detailed, 16:9 landscape.
Supplements

1.000 mg Nicotinamide Riboside saben dina nambah NAD+ ing sel getih kira‑kira 60 % ing wong diwasa tuwa, asil uji coba acak

Dr. Synapse · · 5 min read
#supplements #healthy aging #clinical trial #longevity #nad+ #nicotinamide riboside #arterial stiffness

1.000 mg Nicotinamide Riboside saben dina nambah NAD+ ing sel getih kira‑kira 60 % ing wong diwasa tuwa, asil uji coba acak

Ringkesan

Uji coba crossover ing Nature Communications taun 2018 nyoba Nicotinamide Riboside (NR) 500 mg kaping loro saben dina (total 1.000 mg) nganti enem minggu marang wong diwasa sehat umur setengah umur nganti pra‑tua. Suplemen iki ditampa kanthi apik lan nambah NAD+ ing sel imun getih kira‑kira 60 % tinimbang plasebo. Peneliti uga nyatet sinyal wiwitan babagan tekanan darah sing luwih murah lan kekakuan arteri, nanging iki mung gagasan kanggo uji coba gedhé, ora bukti manfaat sing pasti. Artikel iki nerangake kenapa NAD+ dipikir turun bareng umur, apa sing ditindakake studi, lan apa sing ora bisa diceritakake babagan hasil penyakit utawa umur panjang.

Sawetawis suplemen sing narik perhatian komunitas umur dawa

Ora akèh suplemen sing ngenggoni perhatian komunitas umur dawa kaya Nicotinamide Riboside (NR), sawijining wujud vitamin B3 sing bisa diowahi badan dadi NAD+. Uji coba acak, double‑blind, plasebo‑kontrol sing diterbitake ing Nature Communications taun 2018 tetep dadi salah siji studi manungsa sing paling asring dikutip. Pitakonané prasaja lan praktis: apa wong diwasa sehat umur setengah umur nganti pra‑tua nampa NR saben dina suwene enem minggu aman lan nambah NAD+?

Jawabané loro‑luwé yaiku "ya". Uji coba iki uga menehi petunjuk sing nggumunake nanging durung kabukten babagan tekanan darah lan kekakuan arteri.

Napa NAD+ wigati, lan kenapa mundhak mudhun karo umur

NAD+ (nicotinamide adenine dinucleotide) iku koenzim sing ana ing saben sel. Iki dadi pusat metabolisme energi, lan uga dadi ko‑substrat sing dibutuhaké enzim‑enzim kanggo ngurusi reparasi DNA, tanggapan stres, lan sinyal seluler, kalebu kulawarga sirtuin. Sirtuin wis disambungaké ing riset pra‑klinis karo sawetara manfaat saka pembatasan kalori kanggo ningkatake healthspan.

Ing studi kéwan lan sawetara data jaringan manungsa, kasedhiyan NAD+ katon mudhun bareng umur. Penyebab sing diusulake kalebu peningkatan konsumsi déning enzim sing ngrusak NAD, kaya CD38 lan PARPs, lan owah‑owahan cara sel ngedaur‑ulang lan nggawe NAD+. Gambaran sing cethèk kanggo manungsa isih dikembangaké, lan tingkat penurunané béda‑bèda antar jaringan. Logika sing ndasari uji coba iki prasaja: yèn bioavailabilitas NAD+ winates ing jaringan tuwa, nambah prekursor bisa nulungi. NR minangka salah siji prekursor kuwi.

Dosis lan Desain Uji Coba

Studi iki dipimpin déning peneliti saka University of Colorado Boulder lan kolaboratoré, nganggo desain crossover 2 × 6 minggu (NCT02921659). Saben peserta njupuk loro intervensi, NR lan plasebo, kanthi urutan acak, saéngga saben wong dadi kontrol kanggo dhèwèké déwé. Desain iki cocok kanggo studi fisiologi cilik amarga ngurangi variasi antar individu.

  • Populasi: wong diwasa sehat lan kurus (umur 55–79 taun; rata‑rata BMI kira‑kira 24)
  • Intervensi: nicotinamide riboside 500 mg kaping loro saben dina, total 1.000 mg / hari
  • Pembanding: plasebo sing cocok
  • Durasi: enem minggu saben periode
  • Blinding: double‑blind

Dosis 1.000 mg / hari sing dipérang loro iki luwih dhuwur tinimbang dosis sing umum dipigunakaké ing studi farmakokinetik manungsa awal, mula uji coba iki asring dipigunakaké minangka referensi kanggo dosis kronis.

Asil Utama: NAD+ mundhak kira‑kira 60 %

Penemuan utama yaiku suplemen NR ditampa kanthi apik lan sacara efektif nstimulasi metabolisme NAD+. NAD+ ing sel mononuklear getih periferal (PBMCs), sel imun sing dipisah saka sampel getih, mundhak kira‑kira 60 % tinimbang plasebo.

Loro poin penting kudu digarisbawahi:

  1. PBMCs mung proxy. Sel iki gampang dijangkau, nanging ora padha karo otot, jantung, otak, utawa ati. Nambah NAD+ ing sel getih nuduhaké prekursor diserap lan digunakaké, nanging ora mbuktèkaké manawa NAD+ uga mundhak ing jaringan liya, utawa apa kenaikan kuwi migunani.
  2. Asil biokimia, dudu klinis. Nambah metabolit NAD+ nuduhaké target engagement, nanging ora dadi bukti manfaat klinis.

Babagan keamanan, peneliti nglaporaké yèn suplementasi kronis ing dosis iki ditampa kanthi becik ing kelompok iki, lan iki dadi kontribusi praktis utama saka uji coba.

Sinyal Tekanan Darah lan Kekakuan Arteri

Saliyane metabolisme NAD+, peneliti uga ngétung fungsi fisiologis. Iki sing nuduhaké motivasi kardiovaskular‑umur ing makalah kasebut. Kekakuan arteri gedhé lan tekanan darah sistolik sing mundhak iku ciri utama penuaan vaskular lan faktor risiko utama penyakit kardiovaskular.

Penulis nglaporaké sinyal awal sing patut ditliti luwih lanjut, kalebu tren tekanan darah sing luwih murah lan kecepatan gelombang pulsa karotis‑femoralis (PWV) sing luwih murah, ukuran standar kekakuan aorta. Padha ngandhani kanthi ati‑ati. Uji coba iki ora dirancang utawa cukup kuat kanggo mbuktekaké manfaat vaskular, lan penulis kanthi jelas nyaranaké uji coba klinis mbésuk kanggo mriksa NR ing ngurangi tekanan darah lan kekakuan arteri ing populasi iki.

Bedane penting. Tren ing analisis sekunder cilik mung dadi alasan kanggo ngrancang uji coba sing luwih apik, dudu alasan kanggo ngaku efek pangobatan.

Kesimpulan Praktis

  • Biokimia, kerjane kaya sing dikarepake. Ing dosis 1.000 mg / hari, NR nambah NAD+ PBMC kira‑kira 60 % tinimbang plasebo ing wong diwasa sehat.
  • Tolerabilitas jangka pendek apik. Enem minggu dosis 500 mg kaping loro saben dina ditampa kanthi apik.
  • Aja umumake dosis iki. Temuan iki mung berlaku kanggo produk, dosis, lan populasi sing diteliti. Ora dadi patokan kanggo wong sing nduwèni kondisi medis, ngombe obat, utawa lagi hamil. Konsultasi karo dokter sadurunge suplemen.
  • Anggep efek vaskular minangka hipotesis. Temuan BP lan PWV minangka saran kanggo riset sabanjuré.
  • Priksa kualitas produk. Kemurnian lan dosis suplemen béda‑bèda, lan bahan sing dipigunakaké ing uji coba ora mesthi padha karo sing dijual ing toko. Uga, priksa pendanaan lan konflik kepentingan nalika nimbang riset suplemen sing kagandhengé industri.

Keterbatasan

Uji coba iki cilik lan fokus fisiologi. Ukuran utama yaiku ukuran metabolik lan tolerabilitas, ora titik akhir klinis kaya serangan jantung, stroke, cacat, utawa mortalitas. Peserta sehat lan kurus, mula asil iki ora mesthi bisa ditrapaké kanggo wong obesitas, diabetes, hipertensi, penyakit ginjal, utawa kondisi liyané. Enem minggu uga ora menehi informasi babagan keamanan utawa ketahanan efek sajrone taun‑taun.

Uga penting kanggo jelas apa sing ora dituduhaké studi iki: ora nunjukaké yèn nambah NAD+ ngentekaké proses penuaan, nambah umur urip, utawa nyegah penyakit. NR dudu obat anti‑penuaan, lan makalah iki ora ngaku kuwi.

Kesimpulan Pungkasan

Uji coba Nature Communications 2018 iki minangka langkah awal sing solid: demonstrasi acak, double‑blind, plasebo‑kontrol yèn 1.000 mg / hari NR nambah NAD+ ing sel getih wong diwasa sehat lan katon aman sajrone enem minggu. Apa iki bakal diterjemahaké dadi tekanan darah luwih apik, arteri sing luwih lentur, utawa manfaat kesehatan sing tahan lama, yaiku pitakonan sing kudu dijawab dening uji coba gedhé, suwé luwih dawa, lan ing populasi sing paling mungkin entuk manfaat.

Original study

Read the original research on pubmed.ncbi.nlm.nih.gov →

This article summarizes published research for general information. It is not medical advice.

Share XFacebookLinkedInRedditWhatsApp
DS

Written by

Dr. Synapse

Dr. Synapse writes for Biocracked: biohacking science, longevity & human performance.

Related Articles

Approach: conceptual metaphor. Palette: bold color field. A single AA-style cylindrical battery, shown as a real object with a bare metal cap and a plain unlabeled matte sleeve, stands upright on a glossy surface. It is photographed from a low three-quarter angle against a saturated tomato-red seamless backdrop. The battery is half-filled with a translucent amber liquid that visibly rises inside a clear glass cutaway section. A thin ribbon of electric green light (#00e676) wraps around its base like a charging band. Soft large-softbox light comes from the upper left and produces crisp highlights on the metal and a clean, slightly blurred red reflection beneath it. A second, shorter battery sits out of focus behind, nearly drained and empty, to suggest contrast. The mood is energetic, optimistic and precise, with a tactile product-photography look and shallow depth of field.
supplements

NR + Pterostilbene Nambah NAD+ Kira‑kira 40–90 % ing Uji Manungsa

BY NOVA CHEN ·

Apa kapsul saben dina sing ngandhut nicotinamide riboside lan pterostilbene isa nambah NAD+ ing wong tuwa? Ing uji coba kapisan NRPT (Basis) sing ditindakake ing manungsa, 120 wong umur 60‑80 taun njupuk suplemen iki sajrone wolung minggu. NAD+ ing getih mundhak kira‑kira 40 % kanthi dosis sing disaranake lan 90 % kanthi dosis dobel, lan kenaikan iki tetep stabil nganti pungkasan uji. Ora ana efek samping serius sing dilaporaké.
A softly lit editorial still life on a pale oat-colored linen surface, shot from a slightly elevated three-quarter angle in a wide landscape frame. At center-left, a small matte white ceramic dish holds a modest pile of fine off-white powder, with a tiny brushed-brass measuring spoon resting beside it. Next to the dish stands a minimalist amber glass supplement bottle with a plain cream label and no readable text. A few capsules spill casually across the linen, some translucent and some opaque ivory. On the right side of the composition, a ripe blood orange cut in half and a handful of raw almonds sit on a light ash-wood board. A sprig of fresh rosemary adds a muted green accent. A sheer glass of water catches the light and throws a soft, rippled caustic pattern across the fabric. In the background, out of focus, a woman's hand in a soft sage-green knit sleeve rests near a ceramic mug. This suggests a calm morning routine without showing a face. Behind her, a tall window casts diffused, golden-hour light from the upper left, with gentle shadows and a creamy, shallow depth of field. The palette is warm and restrained: oat, ivory, terracotta, sage, and amber, with a single pop of coral from the blood orange. A thin, abstract line of muted terracotta paint, like a brushed arc, sweeps across the upper right background. It subtly evokes a rising curve without becoming a literal chart. The mood is calm, trustworthy, and contemporary, like a premium wellness and science journal feature. The image has crisp focus on the powder and bottle, natural film-like grain, soft contrast, and generous negative space in the upper third for headline overlay. It looks like a high-end editorial photograph with no text, logos, or futuristic elements.
metabolism

Panemuan Kapisan Manungsa NMN: 250 mg Saben Dina Nambah Sensitivitas Insulin Otot Kira‑kira 25 % ing Wanita Prediabetes

BY DR. SYNAPSE ·

NMN wis suwe dadi idola ing pasar anti‑penuaan, nanging bukti saka manungsa durung kuwat nganti ana uji coba Washington University ing 2021 sing diterbitake ing *Science*. Ing wanita menopause sing kena prediabetes lan kegemukan utawa obesitas, 250 mg NMN saben dina sajrone 10 minggu nambah sensitivitas insulin otot kira‑kira 25 %. Sinyal insulin ing otot lan gén sing kagandheng karo remodeling otot uga membaik, déné kelompok plasebo ora ana owah‑owahan. Nanging keuntungan iki winates, lan studi ora nuduhaké NMN mudhunaké glukosa darah utawa mbalèkaké prediabetes. Ing ngisor iki gambaran apa sing ditemokaké, sapa sing bisa entuk manfaat, lan apa sing ora diganti.
Approach: macro science. Palette: warm (amber and copper). Extreme close-up of a freshly sliced king oyster mushroom stem and gill edge, shot at a slight 30-degree overhead angle with a macro lens and shallow depth of field. The pale cream flesh shows individual fibrous hyphae and glistening moisture beads. Warm low-angle golden light rakes across from the left, turning the gill ridges into amber and copper lines with deep honey-brown shadows. A single tiny droplet on the cut surface catches a pinpoint of electric green reflection, as if lit from a hidden source. Background melts into out-of-focus burnished orange and chocolate tones. The mood is quiet, intimate and investigative, with real organic texture and no text.
longevity

Vitamin Kelonggaran Jamur Nambah NAD+ ing Tikus Tua liwat Saklar H₂S

BY HELIX WARD ·

Ergothioneine, senyawa jamur sing dijuluki "vitamin kelonggaran", saiki wis ditemokaké bisa nambah tingkat NAD+ ing otot lan ningkataké daya tahan treadmill ing tikus tuwa. Mekanisme iki liwat jalur hidrogen sulfida (H₂S) sing melu CSE, persulfidasi, lan enzim cGPDH. Nanging kabeh asil iki saka studi laboratorium lan hewan; dosis sing dipigunakaké kanggo tikus kira‑kira sepuluh kaping luwih dhuwur tinimbang suplemen sing umum dipakai manungsa.
Approach: conceptual metaphor. Palette: bold color field. A single steel bathroom-style analog tape measure, pulled taut and wrapped around a ripe, glossy yellow-orange pear lying on its side, with the tape's tip locked at the same unmarked point, suggesting a waistline that did not shrink. The pear sits on a saturated magenta seamless backdrop, shot from a low three-quarter angle with a shallow depth of field, the stem sharp and the background softly blurred. Hard but slightly diffused studio key light from upper left casts a crisp, short shadow in deeper magenta on the surface. A tiny electric green sticky dot marks the tape's end, with no numbers or writing visible. Mood: playful, skeptical, deadpan, scientific restraint rather than hype.
longevity

Rapamycin Mingguan Sajerone Taun: Aman, Nanging Apa Lemak Visceral Nggowahi?

BY REX MERIDIAN ·

Saben wong kepengin ngerti apa rapamycin mingguan bisa nyuda lemak visceral lan ningkatake healthspan. Uji coba PEARL maringi jawaban sing bisa ngagetaké. Sawisé 48 minggu ing wong diwasa sing sehat, asil utama babagan lemak visceral ora owah, nanging keamanané padha karo plasebo. Sawetara sinyal sekunder – kaya peningkatan massa lean lan rasa nyeri sing luwih sithik ing wanita sing nampa 10 mg, lan rasa kesejahteraan sing luwih apik ing dosis 5 mg – nuduhaké potensi manfaat. Nanging temuan iki asalé saka subkelompok lan laporan diri, rapamycin sing digunakake digawé khusus, lan durung ana bukti yèn iki nambah umur manungsa. Ing ngisor iki apa sing didhukung data lan apa sing ora.

This page is available in

English العربيةবাংলাČeštinaDeutschEspañolفارسیFrançaisHausaहिन्दीHrvatskiBahasa IndonesiaItaliano日本語Basa Jawa한국어NederlandsਪੰਜਾਬੀPolskiPortuguêsRomânăРусскийSrpskiTürkçeУкраїнськаTiếng Việt中文